NANOBIOTIX (NASDAQ: NBTX) issued a statement denying recent media speculation about a potential public takeover of the biotechnology company.

The Paris-based company said it has no knowledge of any intention to acquire control of the company and stated that no process or assessment is being conducted toward that end. NANOBIOTIX also identified factual inaccuracies in the media report that are inconsistent with the company's recent public disclosures.

NANOBIOTIX develops nanotherapeutic approaches for cancer and other diseases. The company was incorporated in 2003 and has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020.

The company operates subsidiaries in Cambridge, Massachusetts, and other locations. NANOBIOTIX holds more than 30 patents associated with three nanotechnology platforms covering oncology, bioavailability and biodistribution, and central nervous system disorders.

The statement was issued in response to media speculation concerning takeover intentions, according to the company's press release.